Digital Trials Digest, our quarterly newsletter
A quarterly look at what's new in ObvioGo, where decentralized trials are heading, and the partnerships shaping what's next — new Image Capture & Central Rating features, caregiver-collected growth data research, and what's coming in OG-2.10.
Issue 2: new Assent & Countersignature capabilities, ObvioGo's direct integration with Oracle Health and Life Sciences, Novotech's multi-trial licensing agreement, and SCOPE 2026 takeaways.
Issue 1: ObvioGo's new built-in eSignature, the Template Library and Out-of-Window Data Submissions features, caregiver-centric eDiary design, and how MiHelper accelerated a decentralized migraine study.
In three short years, decentralized clinical trials (DCTs) have turned skeptics into believers. Trial sponsors who were once hesitant are now embracing the DCT model—and for good reason. Today’s DCTs are addressing longstanding industry challenges, expanding access to patients and clinicians, increasing diversity, accelerating cohort recruitment, and improving retention.
When it comes to decentralized clinical trials (DCTs), the pharmaceutical industry finds itself at a crossroads.
For patients with rare, incurable, or life-threatening diseases, clinical trials can offer new hope. Cancer patients, specifically, are often highly motivated to participate in research, particularly when they have an advanced or treatment-resistant form of cancer. Find out how decentralized clinical trials reach patients in the comfort of their homes.
While there's broad agreement on the gap between white and non-white participation in clinical trial enrollment, the number of non-white patients enrolled in clinical trials for general population studies is still quite low. But why?
Digital instruments such as sensors and wearables are transforming the industry’s definition of accuracy in three measures: volume, practicality, and precision.